Literature DB >> 16958054

Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry.

J L Bernstein1, S Teraoka, M C Southey, M A Jenkins, I L Andrulis, J A Knight, E M John, R Lapinski, A L Wolitzer, A S Whittemore, D West, D Seminara, E R Olson, A B Spurdle, G Chenevix-Trench, G G Giles, J L Hopper, P Concannon.   

Abstract

The ATM gene variants segregating in ataxia-telangiectasia families are associated with increased breast cancer risk, but the contribution of specific variants has been difficult to estimate. Previous small studies suggested two functional variants, c.7271T>G and c.1066-6T>G (IVS10-6T>G), are associated with increased risk. Using population-based blood samples we found that 7 out of 3,743 breast cancer cases (0.2%) and 0 out of 1,268 controls were heterozygous for the c.7271T>G allele (P=0.1). In cases, this allele was more prevalent in women with an affected mother (odds ratio [OR]=5.5, 95% confidence interval [CI]=1.2-25.5; P=0.04) and delayed child-bearing (OR=5.1; 95% CI=1.0-25.6; P=0.05). The estimated cumulative breast cancer risk to age 70 years (penetrance) was 52% (95% CI=28-80%; hazard ratio [HR]=8.6; 95% CI=3.9-18.9; P<0.0001). In contrast, 13 of 3,757 breast cancer cases (0.3%) and 10 of 1,268 controls (0.8%) were heterozygous for the c.1066-6T>G allele (OR=0.4; 95% CI=0.2-1.0; P=0.05), and the penetrance was not increased (P=0.5). These findings suggest that although the more common c.1066-6T>G variant is not associated with breast cancer, the rare ATM c.7271T>G variant is associated with a substantially elevated risk. Since c.7271T>G is only one of many rare ATM variants predicted to have deleterious consequences on protein function, an effective means of identifying and grouping these variants is essential to assess the contribution of ATM variants to individual risk and to the incidence of breast cancer in the population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16958054     DOI: 10.1002/humu.20415

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  41 in total

1.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Authors:  Judy Mouchawar; Christopher Korch; Tim Byers; Todd M Pitts; Efang Li; Margaret R E McCredie; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Authors:  Gerard Lozanski; Amy S Ruppert; Nyla A Heerema; Arletta Lozanski; David M Lucas; Amber Gordon; John G Gribben; Vicki A Morrison; Kanti M Rai; Guido Marcucci; Richard A Larson; John C Byrd
Journal:  Leuk Lymphoma       Date:  2012-06-02

Review 3.  ATM, radiation, and the risk of second primary breast cancer.

Authors:  Jonine L Bernstein; Patrick Concannon
Journal:  Int J Radiat Biol       Date:  2017-07-27       Impact factor: 2.694

Review 4.  ATM mutations for surgeons.

Authors:  Sara A Mansfield; Robert Pilarski; Doreen M Agnese
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

5.  The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.

Authors:  Muzaffer Dükel; W Scott Streitfeld; Tsz Ching Chloe Tang; Lindsey R F Backman; Lingbao Ai; W Stratford May; Kevin D Brown
Journal:  J Biol Chem       Date:  2016-08-17       Impact factor: 5.157

6.  Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.

Authors:  Zhi L Teo; Daniel J Park; Elena Provenzano; Catherine A Chatfield; Fabrice A Odefrey; Tu Nguyen-Dumont; James G Dowty; John L Hopper; Ingrid Winship; David E Goldgar; Melissa C Southey
Journal:  Breast Cancer Res       Date:  2013-02-28       Impact factor: 6.466

7.  Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.

Authors:  Patrick Concannon; Robert W Haile; Anne-Lise Børresen-Dale; Barry S Rosenstein; Richard A Gatti; Sharon N Teraoka; T Anh Diep; Laila Jansen; David P Atencio; Bryan Langholz; Marinela Capanu; Xiaolin Liang; Colin B Begg; Duncan C Thomas; Leslie Bernstein; Jørgen H Olsen; Kathleen E Malone; Charles F Lynch; Hoda Anton-Culver; Jonine L Bernstein
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

8.  Immunodeficiency, radiosensitivity, and the XCIND syndrome.

Authors:  Richard A Gatti; Elena Boder; Robert A Good
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 9.  Counselling framework for moderate-penetrance cancer-susceptibility mutations.

Authors:  Nadine Tung; Susan M Domchek; Zsofia Stadler; Katherine L Nathanson; Fergus Couch; Judy E Garber; Kenneth Offit; Mark E Robson
Journal:  Nat Rev Clin Oncol       Date:  2016-06-14       Impact factor: 66.675

10.  Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

Authors:  M Mitui; S A Nahas; L T Du; Z Yang; C H Lai; K Nakamura; S Arroyo; S Scott; A Purayidom; P Concannon; M Lavin; R A Gatti
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.